Evidence map›Paper›PMID 35242782›Full record

ArticleFrontiers in medicine2022

Comparative Genomics and Characterization of SARS-CoV-2 P.1 (Gamma) Variant of Concern From Amazonas, Brazil.

Ricardo Ariel Zimerman, Patrícia Aline Gröhs Ferrareze, Flavio Adsuara Cadegiani, Carlos Gustavo Wambier, Daniel do Nascimento Fonseca, Andrea Roberto de Souza, Andy Goren, Liane Nanci Rotta, Zhihua Ren, Claudia Elizabeth Thompson

Expression of concernOpen access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Antibody Response in Healthcare Workers During the SARS-CoV-2 Gamma Variant Outbreak in Manaus, Brazil.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. COVID-19 mortality in Brazil, 2020-21: consequences of the pandemic inadequate management.Archives of public health = Archives belges de sante publique · 2022
    Article
  11. Review
  12. Review
  13. A comprehensive review on Covid-19 Omicron (B.1.1.529) variant.Saudi journal of biological sciences · 2022
    Review
  14. Article
  15. Challenges of SARS-CoV-2 Omicron Variant and appropriate countermeasures.Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2022
    Review
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Ricardo Ariel ZimermanHospital da Brigada Militar, Porto Alegre, Brazil.
Patrícia Aline Gröhs FerrarezeGraduate Program in Health Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.
Flavio Adsuara CadegianiCorpometria Institute, Brasília, Brazil.
Carlos Gustavo WambierDepartment of Dermatology, Warren Alpert Medical School of Brown University, Providence, RI, United States.
Daniel do Nascimento FonsecaSamel and Oscar Nicolau Hospitals, Manaus, Brazil.
Andrea Roberto de SouzaSamel and Oscar Nicolau Hospitals, Manaus, Brazil.
Andy GorenApplied Biology, Inc., Irvine, CA, United States.
Liane Nanci RottaGraduate Program in Health Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.
Zhihua RenSuzhou Kintor Pharmaceutical, Inc., Suzhou, China.
Claudia Elizabeth ThompsonGraduate Program in Health Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.
Universidade Federal de Ciências da Saúde de Porto Alegre · BRBrown University · USHospital Alvorada · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundP.1 lineage (Gamma) was first described in the State of Amazonas, northern Brazil, in the end of 2020, and has emerged as a very important variant of concern (VOC) of SARS-CoV-2 worldwide. P.1 has been linked to increased infectivity, higher mortality, and immune evasion, leading to reinfections and potentially reduced efficacy of vaccines and neutralizing antibodies.

methodsThe samples of 276 patients from the State of Amazonas were sent to a central referral laboratory for sequencing by gold standard techniques, through Illumina MiSeq platform. Both global and regional phylogenetic analyses of the successfully sequenced genomes were conducted through maximum likelihood method. Multiple alignments were obtained including previously obtained unique human SARS-CoV-2 sequences. The evolutionary histories of spike and non-structural proteins from ORF1a of northern genomes were described and their molecular evolution was analyzed for detection of positive (FUBAR, FEL, and MEME) and negative (FEL and SLAC) selective pressures. To further evaluate the possible pathways of evolution leading to the emergence of P.1, we performed specific analysis for copy-choice recombination events. A global phylogenomic analysis with subsampled P.1 and B.1.1.28 genomes was applied to evaluate the relationship among samples.

resultsForty-four samples from the State of Amazonas were successfully sequenced and confirmed as P.1 (Gamma) lineage. In addition to previously described P.1 characteristic mutations, we find evidence of continuous diversification of SARS-CoV-2, as rare and previously unseen P.1 mutations were detected in spike and non-structural protein from ORF1a. No evidence of recombination was found. Several sites were demonstrated to be under positive and negative selection, with various mutations identified mostly in P.1 lineage. According to the Pango assignment, phylogenomic analyses indicate all samples as belonging to the P.1 lineage.

conclusionP.1 has shown continuous evolution after its emergence. The lack of clear evidence for recombination and the positive selection demonstrated for several sites suggest that this lineage emergence resulted mainly from strong evolutionary forces and progressive accumulation of a favorable signature set of mutations.

Indexed as

COVID-19genomic epidemiologyNSPP.1phylogenomicsSARS-CoV-2spikeVOC

Identifiers

PMID35242782
PMCPMC8885995
OpenAlexW4213367230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.